A practical guide for providers: help patients find Budesonide/Formoterol (Symbicort) in stock, navigate alternatives, and reduce treatment gaps.
You've written the prescription. Your patient's asthma or COPD is well-controlled on Budesonide/Formoterol. Then the phone call comes: "My pharmacy says they don't have it."
For providers, medication availability issues are an increasingly common clinical headache. Budesonide/Formoterol (Symbicort/Breyna), one of the most widely prescribed ICS/LABA inhalers, experienced significant supply disruptions in 2023–2024. While the situation has improved substantially in 2026 — particularly with generic market entry — your patients may still encounter pharmacy-level stock-outs.
This guide provides a practical workflow for helping patients access their medication efficiently, minimizing treatment gaps and the clinical consequences of missed maintenance therapy.
As of 2026, Budesonide/Formoterol is not on the FDA drug shortage list. The market has expanded to include:
Most availability issues patients report in 2026 are pharmacy-specific (inventory decisions, wholesaler allocations) rather than true market shortages. This means the medication is often available at a different pharmacy even when a patient's usual pharmacy is out.
Understanding the root causes helps you guide patients more effectively:
Major wholesalers (McKesson, Cardinal Health, AmerisourceBergen) sometimes limit how much of a given product each pharmacy can order, even when overall supply is adequate. This affects chain pharmacies more than independents, as chain ordering is often centrally managed.
Some pharmacies — particularly smaller or newer locations — may not stock all strengths or all versions (brand vs. generic) of Budesonide/Formoterol as a default inventory item. They can order it, but may not carry it on the shelf.
When a major insurer shifts Budesonide/Formoterol to a preferred formulary position, pharmacies in that insurer's network can experience sudden demand increases that outpace their inventory cycle.
Respiratory season (October through March) drives higher demand for all inhalers. Patients who refill irregularly during summer may create a wave of refill requests in fall, straining pharmacy stock.
Write prescriptions for "budesonide/formoterol" (generic name) unless there's a specific clinical reason to require brand-name Symbicort. This allows the pharmacy to fill with whichever version is in stock — Symbicort, Breyna, or authorized generic — without needing a new prescription or callback.
Avoid writing "DAW" (Dispense as Written) unless medically necessary. DAW prescriptions force the pharmacy to source a specific product, which can delay filling when that exact product is temporarily unavailable.
Medfinder provides real-time pharmacy stock data that your care team can use to identify pharmacies with current availability. When a patient calls reporting a stock-out:
This workflow typically resolves the issue same-day, avoiding the clinical impact of missed doses.
If your patient has been taking brand-name Symbicort, make sure they know that generic Budesonide/Formoterol is bioequivalent and can be substituted without a clinical difference. Some patients resist generic substitution out of uncertainty — a brief reassurance from their prescriber can remove that barrier.
Generics are also significantly cheaper: $90–$150 with discount cards versus $350–$500 for brand Symbicort. For patients with cost barriers, this substitution alone may improve adherence.
When true unavailability occurs — or when a patient needs an alternative for clinical or insurance reasons — these options are well-supported substitutes:
For a patient-facing comparison of these alternatives, share our alternatives guide.
Cost is often a contributing factor when patients report difficulty filling prescriptions. They may not explicitly say "I can't afford it," but high copays or cash prices can lead to delayed refills and apparent "shortages" from the patient's perspective.
Resources to recommend:
See our provider's guide to helping patients save on Budesonide/Formoterol for more detail.
Consider incorporating these into your standard workflow:
While the worst of the Budesonide/Formoterol supply disruptions are behind us, providers remain a critical link in ensuring their patients maintain uninterrupted access to maintenance therapy. Prescribing generics, leveraging real-time availability tools, and proactively addressing cost barriers are the most effective strategies for minimizing treatment gaps.
The clinical stakes are real: missed ICS/LABA maintenance therapy increases the risk of asthma exacerbations and COPD flare-ups, often resulting in emergency department visits that are far more costly than the medication itself.
For more Budesonide/Formoterol resources, see our provider shortage briefing and drug interactions guide.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
